Drug Trial Radar · NCT02781883
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
May 2016
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Bio-Path Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
BP1001 in combination with Ventoclax plus decitabineDrug
BP1001 in combination with Ventoclax plus decitabine
BP1001 plus decitabineDrug
BP1001 plus decitabine in ventoclax intolerant or resistant subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsyTime frame: 180 days
- Assessment of efficacy in refractory/relapsed AML subjects by bone marrow aspirate or biopsyTime frame: 180 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
University of Kansas Cancer Center
Fairway, Kansas · Recruiting
New Jersey Hematology Oncology Associates
Brick, New Jersey · Terminated
Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Weill Cornell Medical College - New York - Presbyterian Hospital
New York, New York · Recruiting
University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Baylor Scott & White Research Institute
Temple, Texas · Terminated
West Virginia University/Mary Babb Randolph Cancer Center
Morgantown, West Virginia · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.